User:Mr. Ibrahem/Lofexidine

Mr. Ibrahem/Lofexidine
Clinical data
Trade names	Britlofex, Lucemyra, Kai Er Ding, others
Other names	Lofexidine hydrochloride
AHFS/Drugs.com	Monograph
Routes of; administration	By mouth (tablets)
Drug class	α2 adrenergic receptor agonist
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	>90%
Protein binding	80–90%
Metabolism	Liver (glucuronidation)
Elimination half-life	11 hours
Excretion	Kidney
Identifiers
	IUPAC name (RS)-2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole;
Chemical and physical data
Formula	C11H12Cl2N2O
Molar mass	259.13 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES Clc2c(OC(C/1=N/CCN\1)C)c(Cl)ccc2;
	InChI InChI=1S/C11H12Cl2N2O/c1-7(11-14-5-6-15-11)16-10-8(12)3-2-4-9(10)13/h2-4,7H,5-6H2,1H3,(H,14,15) ; Key:KSMAGQUYOIHWFS-UHFFFAOYSA-N ;
	(what is this?) (verify)

Lofexidine, sold under the brand name Lucemyra among others, is a medication used to treat opioid withdrawal.^[2] It is not as effective as buprenorphine.^[3] It is taken by mouth.^[1] It may be used for up to two weeks and should be stopped gradually.^[3]^[2]

Common side effects include trouble sleeping, low blood pressure with standing, slow heart rate, sleepiness, and dry mouth.^[1] Other side effects may include QT prolongation.^[1] Use in pregnancy is of unclear safety.^[1] It is an α₂ adrenergic receptor agonist.^[1]

Lofexidine was approved for use medical use in the United States in 2018.^[1] In the United States 84 tablets of 0.18 mg costs about 1,700 USD as of 2021.^[4] The similar medication clonidine costs less than 10 USD.^[3] It is not commercially available in the United Kingdom as of 2021.^[2]

References[edit]

^ ^a ^b ^c ^d ^e ^f ^g ^h "Lofexidine Monograph for Professionals". Drugs.com. Archived from the original on 18 January 2021. Retrieved 24 November 2021.
^ ^a ^b ^c ^d BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 526. ISBN 978-0857114105.
^ ^a ^b ^c Bryce, Carl (15 March 2019). "Lofexidine (Lucemyra) for Treatment of Opioid Withdrawal Symptoms". American Family Physician. 99 (6): 392–394. ISSN 0002-838X. Archived from the original on 5 March 2021. Retrieved 24 November 2021.
^ "Lucemyra Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 24 November 2021.

[AHFS2021-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h "Lofexidine Monograph for Professionals". Drugs.com. Archived from the original on 18 January 2021. Retrieved 24 November 2021.

[BNF81-2] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 526. ISBN 978-0857114105.

[Step2019-3] Bryce, Carl (15 March 2019). "Lofexidine (Lucemyra) for Treatment of Opioid Withdrawal Symptoms". American Family Physician. 99 (6): 392–394. ISSN 0002-838X. Archived from the original on 5 March 2021. Retrieved 24 November 2021.

[4] "Lucemyra Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 24 November 2021.

[1]

[2]

[3]

[4]